Neurocrine Biosciences (NBIX) Accumulated Expenses (2010 - 2019)

Neurocrine Biosciences (NBIX) has reported Accumulated Expenses for 10 consecutive years, with $46.2 million the latest figure, recorded in Q4 2019.

• For the quarter ending Q4 2019, Accumulated Expenses rose 20.41% year-over-year to $46.2 million; the trailing twelve-month figure through Dec 2019 stood at $46.2 million (up 20.41% YoY), and the FY2019 full-year result was $46.2 million, up 20.41% from the prior year.
• Accumulated Expenses advanced to $46.2 million in Q4 2019 per NBIX's latest filing, from $38.4 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $46.2 million in Q4 2019 and bottomed at $9.6 million in Q4 2016.
• Historically, Accumulated Expenses has averaged $21.0 million across 5 years, with a median of $18.7 million in 2015.
• The sharpest annual moves came in 2016 and 2017: Accumulated Expenses tumbled 49.78% in 2016, then jumped 160.5% in 2017.
• Over 5 years, Accumulated Expenses stood at $19.0 million in 2015, then slumped by 49.78% to $9.6 million in 2016, then surged by 160.5% to $24.9 million in 2017, then soared by 54.13% to $38.4 million in 2018, then climbed by 20.41% to $46.2 million in 2019.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $46.2 million, $38.4 million, and $24.9 million for Q4 2019, Q4 2018, and Q4 2017 respectively.